| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
PURPOSE. To evaluate the efficacy and safety of PKC412, an orally administered kinase inhibitor, in subjects with diabetic macular edema.
METHODS. This was a randomized (1:1:1:1), multicenter, double-masked, parallel-group study in which subjects (n = 141) received placebo or PKC412 (50, 100, or 150 mg/d) for up to 3 months. Subjects were 18 to 85 years of age and had retinal thickening that met predefined criteria and best corrected visual acuity of 55 letters or more. Efficacy was based on changes in retinal thickening measured by grading of fundus photographs and optical coherence tomography (OCT) and changes in visual acuity.
RESULTS. Grading of fundus photographs showed a statistically significant decrease in the area of greatest retinal thickening in patients receiving 150 mg/d of PKC412 (P = 0.032). OCT demonstrated that the two higher doses of PKC412 caused a significant decrease in thickening in the region of greatest thickening and in the fovea (P 
0.039), with response in the high-dose group significantly different from that in the placebo group (difference = -66.69 µm [95.2% CI: -128.57 to -4.81]; P = 0.030). Retinal volume for all locations also showed a significant decrease from baseline in the 100- and 150-mg/d PKC412 groups (P 0.004), and the 150-mg/kg group showed significantly less retinal volume than the placebo group at 3 months (difference = -0.46 mm3 [95.2% CI: -0.86–0.06]; P = 0.019). There was a small (4.36 letters), but significant (P = 0.007), improvement in visual acuity at 3 months compared with baseline in the 100-mg/d PKC412 group. Gastrointestinal side effects (diarrhea, nausea, and vomiting) were the most common adverse events attributed to the drug. Dose-related effects were observed for tolerability, glycemic control, and liver toxicity.
CONCLUSIONS. Orally administered PKC412 at doses of 100 mg/d or higher may significantly reduce macular edema and improve visual acuity in diabetic subjects. However, concern regarding liver toxicity with systemic therapy makes local delivery an appealing approach.
This article has been cited by other articles:
|
|
 |
|
  E. Osto, A. Kouroedov, P. Mocharla, A. Akhmedov, C. Besler, L. Rohrer, A. von Eckardstein, S. Iliceto, M. Volpe, T. F. Luscher, et al. Inhibition of Protein Kinase C{beta} Prevents Foam Cell Formation by Reducing Scavenger Receptor A Expression in Human Macrophages Circulation, November 18, 2008; 118(21): 2174 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, O. Q. P. Yin, P. Graf, J. C. Kisicki, and H. Schran Dose- and Time-Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus J. Clin. Pharmacol., June 1, 2008; 48(6): 763 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Ryan New pharmacologic approachesto treating diabetic retinopathy Am. J. Health Syst. Pharm., September 1, 2007; 64(17_Supplement_12): S15 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The PKC-DMES Study Group Effect of Ruboxistaurin in Patients With Diabetic Macular Edema: Thirty-Month Results of the Randomized PKC-DMES Clinical Trial Arch Ophthalmol, March 1, 2007; 125(3): 318 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vujosevic, E. Midena, E. Pilotto, P. P. Radin, L. Chiesa, and F. Cavarzeran Diabetic Macular Edema: Correlation between Microperimetry and Optical Coherence Tomography Findings. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 3044 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Aiello, A. Clermont, V. Arora, M. D. Davis, M. J. Sheetz, and S.-E. Bursell Inhibition of PKC {beta} by Oral Administration of Ruboxistaurin Is Well Tolerated and Ameliorates Diabetes-Induced Retinal Hemodynamic Abnormalities in Patients Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. He and G. L. King Can Protein Kinase C {beta}-Selective Inhibitor, Ruboxistaurin, Stop Vascular Complications in Diabetic Patients? Diabetes Care, November 1, 2005; 28(11): 2803 - 2805. [Full Text] [PDF]
|
|
|
|
|
|
K. Anzai, S. Yoneya, P. L. Gehlbach, D. Imai, L. L. Wei, and K. Mori Laser Photocoagulation and, to a Lesser Extent, Photodynamic Therapy Target and Enhance Adenovirus Vector-Mediated Gene Transfer in the Rat Retina Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3883 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The PKC-DRS Study Group The Effect of Ruboxistaurin on Visual Loss in Patients With Moderately Severe to Very Severe Nonproliferative Diabetic Retinopathy: Initial Results of the Protein Kinase C {beta} Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial Diabetes, July 1, 2005; 54(7): 2188 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sanchez, L. Zhu, A. F. Brana, A. P. Salas, J. Rohr, C. Mendez, and J. A. Salas From The Cover: Combinatorial biosynthesis of antitumor indolocarbazole compounds PNAS, January 11, 2005; 102(2): 461 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Savage, J. W. Hendrix, D. C. Peterson, H. Young, and C. P. Wilkinson Differences in Pulsatile Ocular Blood Flow among Three Classifications of Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4504 - 4509. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
